NJ State Employees Deferred Compensation Plan Has $910,000 Holdings in Gilead Sciences, Inc. (GILD)

NJ State Employees Deferred Compensation Plan decreased its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 36.4% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 14,000 shares of the biopharmaceutical company’s stock after selling 8,000 shares during the quarter. NJ State Employees Deferred Compensation Plan’s holdings in Gilead Sciences were worth $910,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in GILD. Federated Investors Inc. PA boosted its position in Gilead Sciences by 648.4% during the 3rd quarter. Federated Investors Inc. PA now owns 232,102 shares of the biopharmaceutical company’s stock worth $17,920,000 after purchasing an additional 201,089 shares during the period. Vanguard Group Inc boosted its position in Gilead Sciences by 1.1% during the 3rd quarter. Vanguard Group Inc now owns 97,167,329 shares of the biopharmaceutical company’s stock worth $7,502,290,000 after purchasing an additional 1,071,619 shares during the period. YHB Investment Advisors Inc. boosted its position in Gilead Sciences by 4.7% during the 4th quarter. YHB Investment Advisors Inc. now owns 26,419 shares of the biopharmaceutical company’s stock worth $1,653,000 after purchasing an additional 1,175 shares during the period. Nexus Investment Management Inc. boosted its position in Gilead Sciences by 0.7% during the 4th quarter. Nexus Investment Management Inc. now owns 263,246 shares of the biopharmaceutical company’s stock worth $16,466,000 after purchasing an additional 1,823 shares during the period. Finally, Peoples Financial Services CORP. boosted its position in Gilead Sciences by 70.3% during the 4th quarter. Peoples Financial Services CORP. now owns 1,453 shares of the biopharmaceutical company’s stock worth $91,000 after purchasing an additional 600 shares during the period. Hedge funds and other institutional investors own 80.07% of the company’s stock.

NASDAQ:GILD opened at $65.57 on Friday. The company has a debt-to-equity ratio of 1.09, a current ratio of 3.62 and a quick ratio of 3.56. The stock has a market capitalization of $84.09 billion, a price-to-earnings ratio of 10.66, a PEG ratio of 0.80 and a beta of 1.14. Gilead Sciences, Inc. has a 1-year low of $60.32 and a 1-year high of $79.61.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported $1.76 earnings per share for the quarter, beating analysts’ consensus estimates of $1.53 by $0.23. The company had revenue of $5.28 billion during the quarter, compared to analysts’ expectations of $5.29 billion. Gilead Sciences had a net margin of 26.40% and a return on equity of 37.98%. The firm’s revenue for the quarter was up 3.8% on a year-over-year basis. During the same period in the prior year, the company posted $1.48 EPS. As a group, sell-side analysts expect that Gilead Sciences, Inc. will post 6.6 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, June 27th. Shareholders of record on Friday, June 14th will be given a $0.63 dividend. The ex-dividend date of this dividend is Thursday, June 13th. This represents a $2.52 dividend on an annualized basis and a yield of 3.84%. Gilead Sciences’s payout ratio is currently 40.98%.

In other Gilead Sciences news, Director Richard James Whitley sold 9,534 shares of the company’s stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $65.48, for a total value of $624,286.32. Following the completion of the transaction, the director now directly owns 34,669 shares of the company’s stock, valued at approximately $2,270,126.12. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director John Francis Cogan sold 2,700 shares of the stock in a transaction dated Wednesday, March 20th. The stock was sold at an average price of $65.07, for a total transaction of $175,689.00. Following the transaction, the director now directly owns 57,560 shares in the company, valued at approximately $3,745,429.20. The disclosure for this sale can be found here. Over the last three months, insiders sold 47,670 shares of company stock valued at $3,142,526. 0.20% of the stock is currently owned by corporate insiders.

A number of analysts recently weighed in on the stock. JPMorgan Chase & Co. reaffirmed a “buy” rating and set a $87.00 price target on shares of Gilead Sciences in a research report on Tuesday, May 7th. Needham & Company LLC reaffirmed a “hold” rating on shares of Gilead Sciences in a research report on Monday, May 6th. Raymond James set a $83.00 price target on shares of Gilead Sciences and gave the stock a “buy” rating in a research report on Friday, May 3rd. Cowen reaffirmed a “buy” rating on shares of Gilead Sciences in a research report on Friday, May 3rd. Finally, BidaskClub raised shares of Gilead Sciences from a “sell” rating to a “hold” rating in a research report on Friday, May 3rd. Nine research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $81.61.

TRADEMARK VIOLATION WARNING: This report was originally published by Baseball Daily News and is owned by of Baseball Daily News. If you are reading this report on another site, it was illegally stolen and republished in violation of United States and international copyright laws. The original version of this report can be read at https://www.baseballdailydigest.com/news/2019/05/12/nj-state-employees-deferred-compensation-plan-has-910000-holdings-in-gilead-sciences-inc-gild.html.

About Gilead Sciences

Gilead Sciences, Inc is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. Its primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.

Featured Article: Catch-Up Contributions

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.